Reduced expression of PTEN protein and its prognostic significance in the gastrointestinal stromal tumor

Abstract

Little is reported about the role of PTEN gene in the progression and prognosis of GISTs. This study examined the clinical implications of the tumor suppressor gene PTEN as a prognostic factor in the GISTs. Immunohistological staining and immunoblotting were employed to examine the PTEN protein expression, and its association with clinical measures. Clinicopathological features were reviewed by a retrospective examination of medical records. Reduced PTEN expression was significantly associated with tumor diameter, mitotic figure count, metastasis and pathological stage of tumor (P<0.05), and was not correlated with age, gender and tumor location (P>0.05). The 3-year survival rate of the patients with reduced PTEN expression was significantly lower than those with high PTEN expression (P<0.01). These results suggest that the expression of PTEN gene was significantly linked with the progression and metastasis of GISTs and it is an independent prognostic factor.

Keywords

gastrointestinal stromal tumor / PTEN / prognosis

References

[1] MazurM.T., ClarkH.B.. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol, 1983, 7(6): 507-519

[2] HirotaS., IsozakiK., MoriyamaY., et al.. Gain of function mutations of c-kit in human gastrointestinal stromal tumors. Science, 1998, 279(5350): 577-580

[3] FletcherC.D., BermanJ.J., CorlessC., et al.. Diagnosis of gastrointestinal stromal tumors a consensus approach. Hum Pathol, 2002, 33(5): 459-465

[4] MiettinenM., LasotaJ.. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virehows Arch, 2001, 438(1): 1-12

[5] TranT., DavilaJ.A., El-SeragH.B.. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from. Am J Gastroenterol, 1992, 2005100(1): 162-168

[6] CristofanoA.D., PandolfiP.P.. The multiple roles of PTEN in tumor suppression. Cell, 2000, 100(4): 387-390

[7] LeslieN.R., DownesC.P.. PTEN fuction: How normal cells control it and tumor cells lose it. Biochem J, 2004, 382(1): 1-11

[8] StilesB., GroszerM., WangS., et al.. PTEN less means more. Dev Biol, 2004, 273(2): 175-184

[9] ParsonsR.. Human cancer, PTEN and PI-3 kinase pathway. Semin Cell Dev Biol, 2004, 15(2): 171-176

[10] RheiE., KangL., BogomolniyF., et al.. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res, 1997, 57(17): 3657-3659

[11] TengD.H., HuR., LinH., et al.. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res, 1997, 57(23): 5221-5225

[12] FletcherC.D., BermanJ.J., CorlessC., et al.. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum pathol, 2002, 33(5): 459-465

[13] BermanJ., O’LearyT.J.. Gastrointestinal stromal tumor workshop. Hum Pathol, 2001, 32(6): 578-582

[14] DematteoR.P., HeinrichM.C., EI-RifaiW.M., et al.. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol, 2002, 33(5): 466-477

[15] EisenbergB.L., Von MehrenM.. Pharmacotherapy of gastrointestinal stromal tumors. Expert Opin Pharmacother, 2003, 4(6): 869-874

[16] HeinrichM.C., RubinB.P., LongleyB.J., et al.. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol, 2002, 33(5): 484-495

[17] RubinB.P., SingerS., TsaoC., et al.. KIT activation is a ubiquitous feature of gastrointestinal stomal tumors. Cancer Res, 2001, 61(22): 8118-8121

[18] HeinrichM.C., CorlessC.L., DuensingA., et al.. PDGFRA activating mutations in gastrointestinal stromal tumors. Science, 2003, 299(5607): 708-710

[19] DesaiJ., ShankarS., HeinrichM.C., et al.. Clonal evolution of resistance to imatinib in patients with metastastic gastrointestinal stromal tumors. Clin Cancer Res, 2007, 13(18Pt1): 5398-5405

[20] IsozakiK., HirotaS.. Gain-of-function mutations of receptor tyrosine kinases in gastrointestinal stromal tumors. Curr Genomics, 2006, 7(8): 469-475

[21] LasotaJ., MiettinenM.. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumors. Histopathology, 2008, 53(3): 245-266

[22] HeinrichM.C., MakiR.G., CorlessC.L., et al.. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol, 2008, 26(33): 5352-5359

[23] ZhuX., KwonC.H., SchlosshauerP.W., et al.. PTEN induces G1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res, 2001, 61(11): 4569-4575

[24] RamaswamyS., NakamuraN., VazquezF., et al.. Regulations of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci USA, 1999, 96(5): 2110-2115

[25] TamuraM., GuJ., TakinoT., et al.. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of local adhesion kinase and p130cas. Cancer Res, 1999, 59(2): 442-449

[26] LiD.M., SunHong.. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl Acad Sci USA, 1998, 95(26): 15406-15411